Real-World Data on Retatrutide Reveals Significant Weight Regain and Electrolyte Concerns Post-Treatment

Real-world observations on retatrutide, an investigational triple agonist for weight loss, indicate a 64.2% weight regain at 24 months after discontinuing the drug, accompanied by a decline in resting metabolic rate. Additionally, 14.2% of patients developed clinically significant hypokalemia, highlighting the importance of regular electrolyte monitoring. The findings suggest that adjunctive interventions like resistance training and increased protein intake are crucial to mitigate muscle loss and weight rebound, emphasizing that initial weight loss does not equate to permanent metabolic health.